{
    "clinical_study": {
        "@rank": "97269", 
        "acronym": "US EPIC", 
        "arm_group": [
            {
                "arm_group_label": "Eeva Test Group", 
                "description": "Day 3 embryo transfers that used Eeva with morphology grading (Test Group)."
            }, 
            {
                "arm_group_label": "Matched case control group", 
                "description": "Day 3 embryo transfers using morphology grading only (from concurrent Control Group)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical investigation is to gather data to evaluate the impact of using\n      Eeva with traditional morphology grading on implantation rates."
        }, 
        "brief_title": "US Eeva\u2122 Pregnancy Investigational Clinical Study (US EPIC)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this clinical investigation is to gather data to evaluate the impact of\n      implantation rates for Day 3 embryo transfers using Eeva and morphology grading (test group)\n      versus Day 3 embryo transfers using morphology grading only (from a concurrent control\n      group)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women undergoing fresh in vitro fertilization treatment using their own    eggs or\n             donor eggs.\n\n          -  IVF cycle attempts \u2264 2.\n\n          -  Egg age \u2264 40 years.\n\n          -  Planned Day 3 embryo transfer.\n\n          -  At least 4 normally fertilized eggs (2PN).\n\n          -  All 2PN embryos must be imaged by Eeva.\n\n          -  Ejaculated sperm or sperm from the epididymis (fresh or frozen).\n\n          -  Willing to comply with study protocol and procedures.\n\n          -  Willing to provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Planned preimplantation genetic diagnosis or preimplantation genetic screening.\n\n          -  Planned \"freeze all\" cycle (oocytes or embryos).\n\n          -  Sperm retrieved from testicular tissue.\n\n          -  Abnormal uterine cavity as evaluated by standard methods.\n\n          -  Gestational carrier.\n\n          -  Endometriosis\n\n          -  Hydrosalpinx.\n\n          -  History of cancer.\n\n          -  Concurrent participation in another clinical study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients undergoing in vitro fertilization treatment who provide informed consent and plan\n        to undergo Day 3 embryo transfer."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671657", 
            "org_study_id": "2012-AUX-008"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "In vitro fertilization", 
            "Assisted reproductive therapy", 
            "Time-lapse image recording", 
            "Image analysis software"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "gdadamson@arcfertility.com", 
                "last_name": "G. David Adamson, MD"
            }, 
            "contact_backup": {
                "email": "lourellapalao@fpnc.com", 
                "last_name": "Lourella Palao", 
                "phone": "408-355-1727"
            }, 
            "facility": {
                "address": {
                    "city": "San Jose", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95124"
                }, 
                "name": "Fertility Physicians of Northern California"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "US Eeva\u2122 Pregnancy Investigational Clinical Study (US EPIC)", 
        "overall_contact": {
            "email": "mransom@auxogyn.com", 
            "last_name": "Monica Ransom", 
            "phone": "650-627-7604"
        }, 
        "overall_official": {
            "affiliation": "Auxogyn, Inc.", 
            "last_name": "Shehua Shen, MD, ELD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare implantation rates for the Day 3 embryo transfers that used Eeva with morphology grading (test group) versus Day 3 embryo transfers using morphology grading only (control group).", 
            "measure": "Rate of implantation", 
            "safety_issue": "No", 
            "time_frame": "5-6 gestational age"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate clinical pregnancy rates from the Eeva Test group to the Control group", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks gestational age"
            }, 
            {
                "measure": "Ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "Gestational age week 8-12"
            }, 
            {
                "measure": "Multiple pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "Gestational age weeks 5-6 and 8-12"
            }, 
            {
                "measure": "Spontaneous miscarriage rate", 
                "safety_issue": "No", 
                "time_frame": "Gestational age week 8-12"
            }
        ], 
        "source": "Auxogyn, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Auxogyn, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case Control", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}